The most frequently mutated genes in DLBCL with poor outcomes were KMT2D (32.8%), PIM1 (27.4%), TP53 (26.9%), BCL2 (21.8%), MYD88 (19.9%), TMSB4X (18.2%), HIST1H1E (18.0%), BTG2 (15.7%), and others. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.